While platform players are going super-wide in their offering, some legal AI startups are going the other way and drilling ...

India wants the U.S. to remove all tariffs—both MFN and country-specific—on high and medium-labour-intensive goods. These ...

FY25 adjusted EPS is forecast at €7.36, rising to €9.74 in FY26 and €12.70 in FY27. UCB’s adjusted EBITDA margin is expected to grow from 30% in FY25 to nearly 40% by 2030, driven by Bimzelx and four ...

SmartEsq’s new gen AI offering aims to automate the side letter compiling process and organize provisions to help users ...

India-US trade talks are in the final stage as India pushes for full exemption from the 26% US tariff and duty cuts on key ...

Given that everyone will suffer from these shocks, cooperation to ameliorate them should be a priority, especially for Asia and Europe. Both regions are heavily integrated into the global trading ...

India and the US are engaged in intense trade negotiations in Washington, aiming to finalize an interim trade agreement ...

Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. See ...

CEO of the National Infusion Center Association argues against a drug price control policy known as “most favored nation.” ...

Orforglipron is an oral drug from Eli Lilly that’s in trial stage. The New York Times reports that in a trial of over 500 ...

Yellow Corp. and its largest shareholder urged a federal appeals court panel to overturn a bankruptcy court ruling on what ...